National Institutes of Health to Grant Exclusive License for Anti-Cancer Immunotoxins

Summary

The National Institutes of Health is considering granting a start-up exclusive commercialization license to practice inventions related to anti-cancer immunotoxins, including those targeting the ROR1 receptor, in accordance with federal regulations.